BioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...
Read MoreAptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as aptamer expert, but he will now also take on the role as...
Read MoreAptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the pharmaceutical industry where she has held senior management...
Read MoreAptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to prepare the upcoming...
Read MoreAptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655. With these...
Read MoreBioStock published an article on 2 December 2021 about Aptahem, which can be read in full below. Aptahem’s collaboration with Örebro University recently led to a research breakthrough regarding a newfound pharmacological mechanism behind Aptahem’s sepsis treatment Apta-1. BioStock...
Read MoreAptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has started at the collaboration partner LGC Biotechnologies’ facilities in the USA, with planned delivery date in early 2022. The GMP...
Read MoreAptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studies with Apta-1 treatment shows strong evidence in maintaining systemic circulation, protection of vital organs, regulation of crucial cytokines and preventing hemolysis. Research commissioned...
Read MoreIt is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...
Read MoreOn Thursday 21 October 2021 at 11.40 CET, CEO Mikael Lindstam will present the latest development in Aptahem and the lead candidate Apta-1 at the BioStock Life Science Summit. The event can be followed online via the link: BioStock...
Read More